Navigation Links
GenVec Board Restructures Operations and Withdraws Plan of Dissolution
Date:9/4/2013

GAITHERSBURG, Md., Sept. 4, 2013 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that its Board of Directors withdrew the Plan of Complete Liquidation and Dissolution for the Company previously adopted on May 24, 2013.  The Company also announced that it will pursue a strategy focused on maximizing the value of its technology and assets, including its collaboration with Novartis to develop novel treatments for hearing loss.

In connection with this new operating plan, Cynthia Collins, President and Chief Executive Officer, has departed the Company and resigned as a member of its Board of Directors. Douglas J. Swirsky, who has served as GenVec's Senior Vice President and Chief Financial Officer since 2006, has been named as the Company's President and Chief Executive Officer and has been appointed to the Company's Board of Directors. 

"Under the leadership of Ms. Collins, GenVec has substantially reduced its operating costs over the past several months. GenVec's decision to withdraw its plan of dissolution is a result of our increased confidence that milestones in our collaborations can be realized and our ability to bring our expenditures in line with our resources," noted Mr. Swirsky.  "Not including potential milestone payments from Novartis, we have cash, cash equivalents and investments to fund our operations through at least the end of 2014.  Over the last several months, since the Board approved the plan of dissolution, we have received a number of proposals purported to maximize the value of GenVec's assets.  While we have pursued several of the opportunities that we viewed as potentially viable, they were ultimately not appropriate for any number of reasons, including lack of sufficient funding, or inadequate recognition of the value of GenVec.  During this time, we have grown more confident in the success of our hearing loss program.  We, therefore, believe that shareholders are best served by preserving the Company's hearing loss program and remaining assets within GenVec. In addition, by withdrawing the plan of dissolution, we can also take the time necessary to find licensees or collaborators who assign a reasonable value to our technologies, rather than valuing the technology in the shadow of dissolution."

"On behalf of the Board and everyone at GenVec, I want to thank Cindy for her contributions to the Company over the past 16 months," said Zola Horovitz, Ph.D., Chairman of the Board of Directors. "The Board is confident that this strategy is in the best interest of shareholders and provides the clearest path to value creation."

Following the unanimous approval to withdraw the plan of dissolution and the approval of the operating strategy, directors Edward M. Connor, Jr., M.D., Adel A.F. Mahmoud, M.D., Ph.D., and Kevin M. Rooney resigned from the Company's Board.  The Board now has 5 members.  Dr. Horovitz commented, "We want to thank Drs. Connor and Mahmoud and Mr. Rooney for their service to GenVec's shareholders over the past several years.  Based on the operating strategy, we believe the remaining directors possess the expertise to serve the interests of shareholders while controlling the Company's costs."

Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, such as the failure of Novartis to advance GenVec's hearing loss program, including into human clinical trials.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Retail Investor and Media Contact:

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com

 


'/>"/>
SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
2. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
3. GenVec to Present at 25th Annual ROTH Conference
4. GenVec Reports Third Quarter 2012 Financial Results
5. GenVec Reports Second Quarter 2012 Financial Results
6. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
7. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
8. GenVec Reports Inducement Award
9. GenVec Appoints Cynthia Collins as President and CEO
10. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
11. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
(Date:2/12/2016)... Pharmacy, Inc. (NYSE: DPLO ) is pleased to announce the promotion of Paul ... Jan. 23, 2016. To learn more about ... ... ... In his ...
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... (INS) states that vein visualization technology should be used to ensure patient safety ... the world, the INS Standards mandate the use of vein visualization technology in ...
(Date:2/13/2016)... , ... February 13, 2016 , ... When an Au Pair comes all ... sure what they are in for and they are often worried things won’t go well. ... were hoping for. This year’s Au Pair of the Year winner’s all commented how their ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips ... biography of Rama - Dr. Frederick Lenz. , According to Publisher Roger ... Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love in all ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):